Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374

Antiviral Research

Volumn 49, Issue 2, 2001, Pages 101-114

  Sharmeen, Lamia ^a   McQuade, Thomas ^a   Heldsinger, Andrea ^a   Gogliotti, Rocco ^a   Domagala, John ^a   Gracheck, Stephen ^a  

^a PFIZER INC   (United States)

Author keywords

3 azido 3 deoxythymidine; Antivirals; HIV; Nucleocapsid protein

Indexed keywords

3 METHYL 2 (3 OXO 3H BENZO[D]ISOTHIAZOL 2 YL)PENTANOIC ACID; ANTIVIRUS AGENT; COMPLEMENTARY DNA; INDINAVIR; ISOTHIAZOLE DERIVATIVE; NUCLEOCAPSID PROTEIN; PD 159206; PD 161374; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; LIFE CYCLE; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLES; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0035251052     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00143-1     Document Type: Article

References (39)

1. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts
2. Mutations of RNA and protein sequences involved in humanimmunodeficiency virus type 1 packaging result in production of noninfectious virus
3. Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome
4. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficency syndrome
5. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication
6. HIV causes AIDS
7. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
8. Oscillation of the human immunodeficiency virus surface receptor is regulated the state of viral activation in a CD4 cell model of chronic infection
9. Quantitative analysis of dose effect relationship: The combined effects of multiple drugs or enzyme inhibitors
10. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
11. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy
12. Antiviral properties of RO31-8959, an inhibitor of human immunodeficiency (HIV) proteinase
13. 2,2′-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations
14. Human immunodeficiency virus type 1 nucleocapsid protein can prevent self-priming of minus-strand strong stop DNA by promoting the annealing of short oligonucleotides to Hairpin sequences
15. Cytokine induced expression of HIV-1 in a chronically infected promonocytic cell line
16. Frequent detection and isolation of cytopathic retrovirueses (HTLV-III) from patients with AIDS and at risk for AIDS
17. Genetic analysis of the zinc finger in the Moloney Murine Leukemia virus nucleocapsid domain: Replacement of zinc-coordinating residues with other zinc-coordinating residues yields noninfectious particles containing genomic RNA
18. Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus-and plus-strand transfer
19. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
20. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
21. Human immunodeficiency virus type 1 nucleocapsid protein (Ncp7) directs specific initiation of minus strand DNA synthesis primed by human tRNA in vitro: Studies of viral RNA molecules mutated in regions that flank the primer binding site
22. Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus
23. 3′-Azido-3′-deoxythymidine(BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphoadenopathy-associated virus in vitro
24. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
25. The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity
26. HIV-1 Dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
27. 2,2-Dithiobisbenzamides derived from alpha-, beta-, and gamma amine acids possessing anti-HIV activities: Synthesis and structure-activity relationship
28. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds
29. The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes
30. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS
31. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles
32. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles
33. The in vitro ejection of zinc from humanimmunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamide with cellular anti HIV-activity
34. The human immunodeficiency virus type 1 nucleocapsid protein by disulfide benzamide with cellular anti HIV-activity: Correlation with anti-HIV and virucidal activities
35. Viral dynamics in human immunodeficiency virus type 1 infection
36. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
37. HIV-entry into quiscent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
38. Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation